Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tools to study beta3-adrenoceptors.

Wim Vrydag1, Martin C Michel

  • 1Department Pharmacology and Pharmacotherapy, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, Netherlands.

Naunyn-Schmiedeberg'S Archives of Pharmacology
|January 11, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Botulinum Toxin Type A Injections in the Bladder Wall-An Effective Treatment for Urinary Incontinence with Low Long-Term Adherence.

Toxins·2026
Same author

Letter regarding Pini, A., Nardini, P., Zizi, V., Molino, M., Calvani, M., Carrozzo, F., … Filippi, L. (2026). β3-adrenoceptor agonism exerts lung protection in a rat model of bronchopulmonary dysplasia. Br J Pharmacol, in press.

British journal of pharmacology·2026
Same author

A year in pharmacology: new drugs approved by the US food and drug administration in 2025.

Naunyn-Schmiedeberg's archives of pharmacology·2026
Same author

The Concise Guide to PHARMACOLOGY 2025/26: G protein-coupled receptors.

British journal of pharmacology·2025
Same author

Correction to: Vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomes.

World journal of urology·2025
Same author

Biased Agonism at β-Adrenoceptor Subtypes: A Drug Development Perspective.

Handbook of experimental pharmacology·2025
Same journal

Pharmacological mechanisms of fisetin in neurodegenerative disorders: regulation of neuroinflammatory, oxidative, and autophagic pathways.

Naunyn-Schmiedeberg's archives of pharmacology·2026
Same journal

Isoferulic acid alleviates LPS/D-galactosamine-induced acute liver injury in mice by inhibiting ERK/NF-κB signaling and modulating the NLRP3 inflammasome.

Naunyn-Schmiedeberg's archives of pharmacology·2026
Same journal

Integrated transcriptomic and experimental validation reveal that N‑acetylcysteine ameliorates acute liver failure through multi‑target synergistic regulation of pyroptosis and related signaling networks.

Naunyn-Schmiedeberg's archives of pharmacology·2026
Same journal

Mechanisms of systolic heart failure in PP2CxPP5 double transgenic mice.

Naunyn-Schmiedeberg's archives of pharmacology·2026
Same journal

Adiponectin receptor agonist AdipoRon induces autophagy via AdipoR1/2-AMPK pathway and suppresses tumor progression in ovarian cancer.

Naunyn-Schmiedeberg's archives of pharmacology·2026
Same journal

Injectable bioactive hydrogels as pharmacological drug delivery platforms for post-myocardial infarction cardiac repair: therapeutic cargo engineering, stimuli-responsive release mechanisms, and translational perspectives.

Naunyn-Schmiedeberg's archives of pharmacology·2026
See all related articles

Developing selective tools for beta(3)-adrenoceptors is crucial for treating conditions like overactive bladder. Current agonists and antagonists lack specificity and efficacy, hindering research progress.

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Drug Discovery

Background:

  • Beta(3)-adrenoceptors are key targets for treating overactive bladder syndrome.
  • Understanding beta(3)-adrenoceptor function is limited by a lack of specific research tools.

Purpose of the Study:

  • To highlight the limitations of current beta(3)-adrenoceptor agonists and antagonists.
  • To emphasize the urgent need for more selective and efficacious beta(3)-adrenoceptor research tools.

Main Methods:

  • Review of existing beta(3)-adrenoceptor agonists (e.g., BRL 37,344, CGP 12,177) and antagonists (e.g., SR 59,230).
  • Discussion of limitations including partial agonism, lack of selectivity, and off-target effects.
  • Consideration of genetically modified mouse models and their limitations for human extrapolation.

Related Experiment Videos

Main Results:

  • Classical beta(3)-adrenoceptor agonists exhibit partial efficacy and limited selectivity.
  • The widely used antagonist SR 59,230 demonstrates poor selectivity and potential partial agonism in humans.
  • A significant lack of selective radioligands for beta(3)-adrenoceptors exists.

Conclusions:

  • Current pharmacological tools for beta(3)-adrenoceptor research are inadequate.
  • Further development of selective agonists, antagonists, and radioligands is urgently required.
  • Researchers must acknowledge the limitations of existing tools in current studies.